Chartwell Investment Partners LLC reduced its holdings in bluebird bio Inc (NASDAQ:BLUE) by 28.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 9,686 shares of the biotechnology company’s stock after selling 3,782 shares during the period. Chartwell Investment Partners LLC’s holdings in bluebird bio were worth $1,725,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. lifted its position in shares of bluebird bio by 2,110.3% in the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares during the last quarter. NuWave Investment Management LLC bought a new position in shares of bluebird bio in the 4th quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares during the last quarter. QS Investors LLC lifted its position in shares of bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of bluebird bio in the 4th quarter worth about $247,000.
In other bluebird bio news, COO Susanna Gatti High sold 1,282 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the sale, the chief operating officer now directly owns 13,718 shares in the company, valued at approximately $2,361,553.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Davidson sold 4,000 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 200,280 shares of company stock worth $37,818,846 over the last 90 days. 3.90% of the stock is owned by insiders.
A number of research analysts have recently issued reports on the stock. Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 3rd. Leerink Swann downgraded shares of bluebird bio from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $162.00 to $194.00 in a research report on Thursday, January 25th. Maxim Group set a $170.00 price objective on shares of bluebird bio and gave the company a “buy” rating in a research report on Friday, November 17th. CIBC started coverage on shares of bluebird bio in a research report on Thursday, December 21st. They issued a “market perform” rating on the stock. Finally, BidaskClub upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 26th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. bluebird bio has an average rating of “Hold” and an average target price of $161.45.
Shares of bluebird bio Inc (NASDAQ BLUE) opened at $205.45 on Wednesday. bluebird bio Inc has a 52-week low of $73.95 and a 52-week high of $222.03. The company has a market cap of $10,460.19, a PE ratio of -29.27 and a beta of 2.07.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.